Press Releases

December 3, 2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia Read More
November 13, 2019
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences Read More
November 6, 2019
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results Read More
November 6, 2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease Read More
October 31, 2019
Protagonist Therapeutics Secures Debt Facility for up to $50 Million Read More
October 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera Read More
October 1, 2019
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting Read More
September 25, 2019
Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 Read More
September 4, 2019
Protagonist Therapeutics Reports Granting of Inducement Awards Read More
September 3, 2019
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference Read More
August 7, 2019
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results Read More
August 1, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study Read More
July 16, 2019
Protagonist Therapeutics Reports Granting of Inducement Award Read More
June 18, 2019
Protagonist Therapeutics Reports Granting of Inducement Award Read More
June 17, 2019
Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference Read More
June 4, 2019
Protagonist Therapeutics Reports Granting of Inducement Award Read More
May 29, 2019
Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer Read More
May 14, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study Read More
May 8, 2019
Protagonist Therapeutics Reports First Quarter 2019 Financial Results Read More
May 8, 2019
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists Read More